Humana · Letermovir · US health-plan appeal rights

Letermovir denied for failing step therapy by Humana?

Q: How long do I have to appeal a Humana Letermovir denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for letermovir are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Letermovir (Prevymis) Prior Authorization for CMV Prophylaxis

The Humana angle on Letermovir

## Why Humana Requires Step Therapy for Letermovir — and How to Appeal

Humana's step-therapy protocol for letermovir typically requires documentation that an older or lower-cost antiviral agent was tried first for CMV prophylaxis, or that such an agent is clinically inappropriate for the patient. For transplant recipients, step-therapy protocols can create dangerous delays because CMV prophylaxis must begin within a specific post-transplant window. An inadequate first-step agent or any delay can result in CMV disease with serious clinical consequences. This urgency, combined with letermovir's distinct mechanism of action and guideline support, makes step-therapy denials for this drug among the most clinically important — and most reversible — appeal types.

## The Federal Legal Framework

ERISA §503: employer-sponsored plans must provide a full-and-fair review with written explanation of which step-therapy criteria were not met.
ACA §2719: independent external review is available within approximately four months of denial. Expedited review (72-hour response) applies when delay in prophylaxis poses immediate risk to the transplant patient.
State step-therapy exception laws: many states require insurers to grant a step-therapy exception when the required first-step drug is contraindicated, has previously failed, causes an adverse reaction, or when clinical urgency makes the step-therapy protocol inappropriate. Identify whether your state has such a law and assert it explicitly.

## Concrete Appeal Steps and Timeline

1. Request the step-therapy criteria: Humana must provide the specific drugs in the step sequence and the criteria for bypassing them. 2. File a step-therapy exception request simultaneously with the internal appeal — this is frequently the fastest resolution path. 3. Expedited internal review: request this immediately; the prescriber must certify that the standard timeline would jeopardize the patient's health. Humana must respond within 72 hours. 4. Peer-to-peer call: the transplant prescriber should request an urgent peer-to-peer with Humana's medical director to explain the clinical urgency and the inadequacy of the required first-step agent. 5. External review: if the exception and internal appeal are denied, file for IRO review immediately given the prophylaxis timing stakes.

## Documentation to Gather

Contraindication or failure of required step: chart documentation that the first-step agent Humana requires either (a) was previously tried and failed, (b) carries a contraindication for this patient, (c) has a clinically significant interaction with the current immunosuppression regimen, or (d) is not guideline-recommended for this patient's specific CMV risk profile.
Transplant and CMV records: transplant type, date, donor/recipient CMV serostatus, immunosuppression protocol — the foundation of any letermovir appeal.
Clinical urgency documentation: a note from the transplant team establishing the prophylaxis initiation window and documenting that waiting for step-therapy completion would fall outside that window or create clinically unacceptable risk.
Prescriber letter: a letter from the transplant physician or transplant infectious disease specialist that addresses each step-therapy criterion, explains why the required step is inappropriate for this patient, and references the relevant transplant guideline organization's recommendation for letermovir in this risk category.
Humana's step-therapy policy and exception criteria: obtain both before writing the appeal.

## Criteria-Mapping Structure

Build a two-column table: left column, each step in Humana's required sequence and the exception criteria; right column, the specific chart fact or clinical explanation that satisfies the exception. The most powerful arguments are prior failure, contraindication, or clinical urgency — any of these, well-documented, typically results in the step being waived at the peer-to-peer or first internal review level. Do not allow step-therapy protocol to delay post-transplant CMV prophylaxis without exhausting every expedited appeal option available.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other denial reasons for Humana Letermovir

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.